DEF 14C: Impact BioMedical Converts $12M Debt to Equity with DSS

Impact BioMedical Inc. will issue 31.9 million common shares to DSS, Inc. to convert a $12 million debt, making DSS the majority common shareholder.

Summary

• Impact BioMedical Inc. (the Company) is issuing up to 31,939,778 shares of its common stock to DSS, Inc. (DSS) to convert an outstanding debt.
• This action stems from a Debt Conversion Agreement entered into on July 21, 2025, related to a revolving promissory note with an original amount of $12,000,000.
• The conversion will result in DSS beneficially owning approximately 73.62% of the Company's outstanding common stock, increasing its total common shares to 32,484,802.
• The Corporate Actions were approved by unanimous written consent of the Board of Directors and by written consent of holders of a majority of the voting power of the Company's issued and outstanding capital stock on July 14, 2025.
• No further stockholder vote or action is required, and the actions will become effective no sooner than 20 days after the definitive Information Statement is mailed to shareholders, expected around September 29, 2025.

Sentiment

Score: 6

Explanation: The debt-to-equity conversion resolves a significant liability, which is a positive step for the balance sheet. However, it comes at the cost of substantial dilution for existing common shareholders and significantly increases DSS, Inc.'s control, creating a mixed sentiment. The action was expected given the related-party debt.

Positives

• Resolution of a significant outstanding debt of $8,878,000 (as of December 31, 2024) owed to DSS, Inc., improving the Company's balance sheet by converting debt to equity.
• Elimination of future interest payments on the converted portion of the revolving promissory note.

Negatives

• Significant dilution for existing common stockholders due to the issuance of 31,939,778 new common shares.
• Increased control by DSS, Inc., which will own approximately 73.62% of the Company's outstanding common stock post-conversion, potentially limiting the influence of other shareholders.

Risks

• Shareholder Dilution: The issuance of over 31.9 million new common shares will significantly dilute the ownership percentage and voting power of existing common stockholders not affiliated with DSS, Inc.
• Concentrated Ownership: DSS, Inc. will become the dominant common shareholder with approximately 73.62% ownership, potentially leading to decisions that primarily benefit DSS, Inc.
• Related Party Dependence: Continued reliance on DSS, Inc. for operational support and past financial arrangements, as evidenced by ongoing general and administrative cost pass-throughs and the history of the revolving promissory note.

Future Outlook

The filing contains standard forward-looking statements, cautioning that actual outcomes and results may differ materially from expectations due to inherent risks, uncertainties, and assumptions that cannot be predicted.

Industry Context

This filing primarily details a corporate financial restructuring event (debt-to-equity conversion) and does not provide information directly related to broader industry trends or competitive positioning within the biomedical sector.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings involving directors or executive officers requiring disclosure under Item 401(f) of Regulation S-K were mentioned in the filing.

Related Party Transactions

• The Company previously funded scientific operations of GRDG, a minority stockholder of two Company subsidiaries, under a Shareholders Agreement (ended September 2023).
• A Licensing Proceeds Distribution Agreement with GRDG (February 15, 2022) involved GRDG transferring equity in subsidiaries for a 20% interest in licensing/sale revenue, with expenses of $25,000 in 2024 and $447,000 in 2023.
• DSS, Inc. (a related party) passes through general and administrative costs to the Company, totaling $357,000 in 2024 and $144,000 in 2023.
• A Revolving Promissory Note with DSS, Inc. (executed December 31, 2020, amended January 18, 2024, and July 24, 2024) had an outstanding balance of $8,878,000 as of December 31, 2024, and $12,074,000 as of December 31, 2023. This note is the subject of the debt conversion.

Stakeholder Impact

• Shareholders: Existing common shareholders will experience significant dilution of their ownership percentage and voting power due to the issuance of over 31.9 million new shares to DSS, Inc.
• DSS, Inc.: Will convert its debt into a controlling equity stake of approximately 73.62% of the Company's common stock, solidifying its influence and potentially benefiting from future company performance.
• Creditors: The conversion of a significant debt obligation to equity reduces the Company's leverage and improves its balance sheet, potentially viewed positively by other creditors.

Next Steps

• The Corporate Actions, including the debt conversion, will become effective no sooner than 20 days after the definitive Information Statement is mailed to stockholders (expected around September 29, 2025).
• The Company will continue to operate under the new ownership structure and management.

Key Dates

Recommendation

The debt-to-equity conversion addresses a significant financial liability, which is a positive step for the Company's balance sheet and long-term viability. However, the substantial dilution for existing common shareholders and the increased control by DSS, Inc. (now owning over 73% of common stock) introduce new considerations. While the resolution of debt is favorable, the immediate impact on per-share value and the concentration of ownership warrant a 'hold' recommendation, as the market will need to digest the implications of this significant restructuring and its long-term effects on governance and strategic direction.

Keywords

Impact BioMedical, DSS Inc, Debt Conversion, Equity Issuance, SEC Filing, DEF 14C, Common Stock, Shareholder Dilution, Corporate Governance, Related Party Transaction, Financial Restructuring